William B. Hillegass

Dr. William B. Hillegass

Departments of Data Science, Population Health, and Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in Hypertension
Verified
Journal Article
Closed access
PDF file
ALAisha T. Langford
Aisha T. Langford
OAOluwasegun P. Akinyelure
Oluwasegun P. Akinyelure
TMTony L. Moore
Tony L. Moore
GHGeorge Howard
George Howard
YMYuan-I Min
Yuan-I Min
PMPaul Muntner
Paul Muntner
Resistant hypertension, defined as blood pressure levels above goal while taking ≥3 classes of antihypertensive medication or ≥4 classes regardless of blood pressure level, is associated with increased cardiovascular disease risk. The 2018 American Heart Association Scientific Statement on Resistant Hypertension recommends healthy lifestyle habits and thiazide-like diuretics and mineralocorticoid receptor antagonists for adults with resistant hypertension. The term apparent treatment-resistant hypertension (aTRH) is used when pseudoresistance cannot be excluded. We estimated the use of healthy lifestyle factors and recommended antihypertensive medication classes among US Black adults with aTRH. Data were pooled for Black participants in the JHS (Jackson Heart Study) in 2009 to 2013 (n=2496) and the REGARDS study (Reasons for Geographic and Racial Differences in Stroke) in 2013 to 2016 (n=3786). Outcomes included lifestyle factors (not smoking, not consuming alcohol, ≥75 minutes of vigorous-intensity or ≥150 minutes of moderate or vigorous physical activity per week, and body mass index <25 kg/m 2 ) and recommended antihypertensive medications (thiazide-like diuretics and mineralocorticoid receptor antagonists). Overall, 28.3% of participants who reported taking antihypertensive medication had aTRH. Among participants with aTRH, 14.5% and 1.2% had ideal levels of 3 and 4 of the lifestyle factors, respectively. Also, 5.9% of participants with aTRH reported taking a thiazide-like diuretic, and 9.8% reported taking a mineralocorticoid receptor antagonist. In conclusion, evidence-based lifestyle factors and recommended pharmacological treatment are underutilized in Black adults with aTRH. Increased use of lifestyle recommendations and antihypertensive medication classes specifically recommended for aTRH may improve blood pressure control and reduce cardiovascular disease–related morbidity and mortality among US Black adults. Graphic A graphic abstract is available for this article.

22 March 2022 in Respiration
Verified
Journal Article
Open access
PDF file
MSMichal Senitko
Michal Senitko
COCatherine L. Oberg
Catherine L. Oberg
GAGeorge E. Abraham
George E. Abraham
WHWilliam B. Hillegass
William B. Hillegass
IAIsrah Akhtar
Israh Akhtar
EFErik Folch
Erik Folch
Background: Malignant central airway obstruction (CAO) is a debilitating complication of primary lung cancer and pulmonary metastases. Therapeutic bronchoscopy is used to palliate symptoms and/or bridge to further therapy. Microwave ablation (MWA) heats tissue by creating an electromagnetic field around an ablation device. We present a pilot study utilizing endobronchial MWA via flexible bronchoscopy as a novel modality for the management of malignant CAO. Methods: Therapeutic bronchoscopy with a flexible MWA probe was performed in 8 cases. We reviewed tumor size, previous ablative techniques, number of applications, ablation time, amount of energy delivered, rate of successful recanalization, complications, and 30-day follow-up. Results: Successful airway recanalization was achieved in all cases. No complications were noted. In 1 case, tumor in-growth within a silicone stent was ablated with no damage to the stent. Discussion: Endobronchial MWA is a novel technique for tumor destruction while maintaining an airway axis. The oven effect and air gap around a tumor allow for safe and effective tissue devitalization and hemostasis without a thermal effect on structures surrounding the airway.

1 July 2011 in Vascular Health and Risk Management
Verified
Journal Article
Open access
WHWilliam B. Hillegass
William B. Hillegass
Peer reviewed article authored by (Hillegass WB, Brott BC, Dobbs JC, Papapietro SE, Misra VK, Zoghbi GJ). Read article or submit your manuscript for publishing.

5 January 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAlfred Jerrod Anzalone
Alfred Jerrod Anzalone
JSJing Sun
Jing Sun
AVAmanda Jean Vinson
Amanda Jean Vinson
WBWilliam H. Beasley
William H. Beasley
WHWilliam B. Hillegass
William B. Hillegass
OCon behalf of the National COVID Cohort Collaborative (N3C) Consortium
on behalf of the National COVID Cohort Collaborative (N3C) Consortium
Background: While COVID-19 vaccines reduce adverse outcomes, post-vaccination SARS-CoV-2 infection remains problematic. We sought to identify community factors impacting risk for breakthrough infections (BTI) among fully vaccinated persons by rurality. Methods: We conducted a retrospective cohort study of US adults sampled between January 1 and December 20, 2021, from the National COVID Cohort Collaborative (N3C). Using Kaplan-Meier and Cox-Proportional Hazards models adjusted for demographic differences and comorbid conditions, we assessed impact of rurality, county vaccine hesitancy, and county vaccination rates on risk of BTI over 180 days following two mRNA COVID-19 vaccinations between January 1 and September 21, 2021. Additionally, Cox Proportional Hazards models assessed the risk of infection among adults without documented vaccinations. We secondarily assessed the odds of hospitalization and adverse COVID-19 events based on vaccination status using multivariable logistic regression during the study period. Results: Our study population included 566,128 vaccinated and 1,724,546 adults without documented vaccination. Among vaccinated persons, rurality was associated with an increased risk of BTI (adjusted hazard ratio [aHR] 1.53, 95% confidence interval [CI] 1.42–1.64, for urban-adjacent rural and 1.65, 1.42–1.91, for nonurban-adjacent rural) compared to urban dwellers. Compared to low vaccine-hesitant counties, higher risks of BTI were associated with medium (1.07, 1.02–1.12) and high (1.33, 1.23–1.43) vaccine-hesitant counties. Compared to counties with high vaccination rates, a higher risk of BTI was associated with dwelling in counties with low vaccination rates (1.34, 1.27–1.43) but not medium vaccination rates (1.00, 0.95–1.07). Community factors were also associated with higher odds of SARS-CoV-2 infection among persons without a documented vaccination. Vaccinated persons with SARS-CoV-2 infection during the study period had significantly lower odds of hospitalization and adverse events across all geographic areas and community exposures. Conclusions: Our findings suggest that community factors are associated with an increased risk of BTI, particularly in rural areas and counties with high vaccine hesitancy. Communities, such as those in rural and disproportionately vaccine hesitant areas, and certain groups at high risk for adverse breakthrough events, including immunosuppressed/compromised persons, should continue to receive public health focus, targeted interventions, and consistent guidance to help manage community spread as vaccination protection wanes.

1 May 2016 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
WHWilliam B. Hillegass
William B. Hillegass
NLNita A. Limdi
Nita A. Limdi
Opinion from JAMA Cardiology — Valvular Heart Disease and Acquired Type 2A von Willebrand Syndrome — The “Hemostatic” Waring Blender Syndrome

8 September 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BHBrittain Heindl
Brittain Heindl
SCStephen Clarkson
Stephen Clarkson
VPVibhu Parcha
Vibhu Parcha
CDChrisly Dillon
Chrisly Dillon
RNRenuka Narayan
Renuka Narayan
NLNita Limdi
Nita Limdi
Background: Dual antiplatelet therapy after percutaneous coronary intervention reduces myocardial infarctions but increases bleeding. The risk of bleeding may be higher among Black patients for unknown reasons. Bleeding risk scores have not been validated among Black patients. We assessed the difference in bleeding risk between Black and White patients along with the performance of the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Anti Platelet Therapy, Patterns of Nonadherence to Antiplatelet Regimens in Stented Patients, and Academic Research Consortium for High Bleeding Risk scores among both groups. Methods and Results: This was a single‐center prospective study of patients who underwent percutaneous coronary intervention (2014–2019) and were followed for 1 year. The outcome was postdischarge Bleeding Academic Research Consortium 2 to 5 bleeding. Incidence rates were reported. Cox proportional hazards models measured the effect of self‐reported Black race on bleeding and determined the predictors of bleeding among 19 a priori variables. The 3 risk scores were assessed among Black and White patients separately using the Harrell concordance index. Of 1529 included patients, 342 (22.4%) self‐reported as being Black race. Unadjusted bleeding rates were 22.7 per 100 person‐years among Black patients versus 16.3 among White patients (hazard ratio, 1.41 [95% CI, 1.00–2.00], P =0.052). Predictors of bleeding were age, glomerular filtration rate <30 mL/min per 1.73 m 2 , prior bleeding, ticagrelor or prasugrel use, and anticoagulant use. Among Black and White patients, respectively, the C‐indexes were the following: 0.644 versus 0.600 for Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Anti Platelet Therapy ( P <0.001 for both), 0.620 versus 0.612 for Patterns of Nonadherence to Antiplatelet Regimens in Stented Patients ( P =0.003 and P <0.001, respectively), and 0.600 versus 0.598 for Academic Research Consortium for High Bleeding Risk ( P =0.006 and P <0.001, respectively). Conclusions: The risk of dual antiplatelet therapy–associated postdischarge Bleeding Academic Research Consortium 2 to 5 bleeding was not significantly different between self‐reported Black and White patients. Bleeding risk scores performed similarly among both groups.